首页> 外文期刊>American Journal of Ophthalmology: The International Journal of Ophthalmology >Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis.
【24h】

Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis.

机译:眼周曲安奈德注射液用于囊状黄斑水肿并发非感染性葡萄膜炎。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: To describe the effectiveness of periocular corticosteroid injections in the treatment of cystoid macular edema (CME) complicating noninfectious uveitis. DESIGN: Retrospective cohort study. METHODS: A total of 126 patients (156 eyes) were evaluated for presence of CME, visual acuity, intraocular pressure, degree of intraocular inflammation, and the presence of ocular complications. Main outcome measures included resolution of CME and visual acuity at the 1- and 3-month visits, failure of periocular injection therapy, and side effects. RESULTS: Twenty-eight percent of the 156 eyes had anterior uveitis, 22% intermediate uveitis, and 31% panuveitis. Of these eyes, 53% demonstrated clinical resolution of CME at 1 month and 57% at 3 months after a single periocular corticosteroid injection. Forty eyes were treated with >1 periocular injection because the CME persisted 1 month after the first injection (1 additional injection in 21 eyes; 2 additional injections in 14 eyes; >2 additional injections in 5 eyes). For the 21 eyes treated with a second periocular corticosteroid injection, 81% had no CME 1 month after the second injection and 48% had no CME 3 months after the second injection. Twenty-three eyes (15%) failed periocular corticosteroid therapy. Of eyes initially responding to periocular injection, CME recurred in 53% (median time to recurrence = 20.2 weeks). A halving of the visual angle was observed in 52% and 57% at the 1- and 3-month visits after injection, respectively. CONCLUSIONS: Fifty-three percent of eyes treated with a single periocular corticosteroid injection had clinical resolution of CME 1 month after the injection.
机译:目的:描述眼周皮质类固醇注射液在治疗非感染性葡萄膜炎并发囊性黄斑水肿(CME)中的有效性。设计:回顾性队列研究。方法:对总共126例患者(156眼)进行了CME,视力,眼内压,眼内炎症程度和眼部并发症的评估。主要结局指标包括1个月和3个月就诊时CME的分辨率和视敏度,眼周注射疗法的失败以及副作用。结果:156只眼中有28%患有前葡萄膜炎,22%的中间葡萄膜炎和31%的葡萄膜炎。这些眼睛中,有53%的患者在单次眼周注射皮质类固醇激素后1个月表现出CME的临床症状,在3个月时表现出57%的临床症状。因为CME在第一次注射后1个月持续存在,所以用> 1次眼周注射治疗了40眼(21眼额外1次注射; 14眼额外2次注射; 5眼额外2次注射)。对于第二次眼周皮质类固醇注射治疗的21只眼睛,第二次注射后1个月无CME的占81%,第二次注射3个月后无CME的占48%。 23眼(15%)的眼周皮质激素治疗失败。在最初对眼周注射作出反应的眼睛中,CME复发了53%(中位复发时间= 20.2周)。注射后1个月和3个月时,分别有52%和57%的人将视角减半。结论:单次眼周皮质类固醇注射治疗的眼睛中有53%在注射后1个月具有CME的临床分辨率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号